SOLICITATION NOTICE
Q -- HPV serologic testing for the study entitled “Prospective evaluation of HPV prior to diagnosis of incident head and neck cancer and anogenital cancer”
- Notice Date
- 12/17/2014
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52515-83
- Archive Date
- 1/27/2015
- Point of Contact
- Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis the services for HPV serologic testing with German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, D- 9120 Heidelberg Germany. This process will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is $14 million. Only one award will be made as a result of this solicitation. This will be awarded as an Indefinite Delivery Indefinite Quantity (IDIQ) type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The period of performance is for twelve months from time of award plus one twelve month Option Period. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. Human papillomavirus (HPV) is the cause of cervical cancer, as well as subsets of cancers at other anatomic sites, including the oropharynx, vulva/vagina, penis, and anus. NCI recently reported that HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of oropharyngeal cancer cases and 0.6% of controls. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. NCI now aims to confirm our initial finding by testing additional samples from other studies, and to expand our research to anogenital cancers, in order to understand whether this potential cancer biomarker is unique to HPV-driven oropharyngeal cancer, or also predicts risk at other anatomic sites where HPV is known to be a causal factor. Next, this sole source procurement is to provide laboratory testing for HPV serology to support this NCI-IARC collaborative case-control study. The study has 3 aims: 1. Confirm the main effects of HPV on cancer at several anatomic sites of the head and neck 2. Expand evaluation to cancers of the anogenital region 3. Investigate the specificity of the marker in people without cancer. As described in detail above, the contractor shall perform HPV testing of serum samples from cases and controls. Lastly, DKFZ is the only known lab in the world that runs a Luminex-based serologic assay for the necessary HPV genotypes and proteins. In addition NCI is looking to confirm or refute previous findings on new samples from other cohort studies; thus it is imperative to use the same assay for the contingency of the experiment. This is not a solicitation for competitive quotations. However, if any interested party especially a small business, believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, January 12, 2014. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Gwennifer Epps, Contracting Officer at ge50d@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP52515-83 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52515-83 /listing.html)
- Place of Performance
- Address: Nationa Cancer Institute, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03598575-W 20141219/141217234503-dbf7a48f646b9047ea096317307ba740 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |